Cargando…
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial
BACKGROUND: We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR) over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III non-small-cell lung cancer (NSCLC). METHODS: Between January 2009 and November 2011, 40 eligible...
Autores principales: | Yao, Lei, Xu, Shidong, Xu, Jianyu, Yang, Chaoyang, Wang, Junfeng, Sun, Dawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311504/ https://www.ncbi.nlm.nih.gov/pubmed/25572571 http://dx.doi.org/10.1186/s13014-014-0306-3 |
Ejemplares similares
-
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial
por: Feng, Junfei, et al.
Publicado: (2016) -
Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020) -
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]
por: Yokoyama, A., et al.
Publicado: (1998) -
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis
por: Zhang, Peng, et al.
Publicado: (2016) -
S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials
por: Qie, Shuai, et al.
Publicado: (2018)